Illumina, Inc. today announced that it has appointed Paula Dowdy to lead the Europe, Middle East and Africa (EMEA) commercial team as Senior Vice President and General Manager.
Paula was previously Senior Vice President for Cloud, Software, and Managed Services at Cisco.
“We are truly excited for Paula to lead our EMEA commercial operations team,” said Christian Henry, Executive Vice President for Commercial Operations. “Paula brings a proven track record of leadership, insight and execution, and her passion for delivering customer success will serve the EMEA region exceptionally well. Additionally, this hire supports our strategy to bring in expertise from large-scale companies to complement our leadership team.”
Paula joined Cisco 20 years ago and has spent the majority of her career in Europe. She has held numerous senior positions leading Cisco product and services groups for virtually all customer segments. In her most recent role, Paula led Cisco’s go-to-market team for Cloud, Software, and Managed Services where she drove the incubation of innovative new solutions.
Paula holds an MBA degree from Pepperdine University and a Bachelor of Arts degree from the University of California, Berkeley. Paula will officially join Illumina August 1, 2016.
Source: Illumina
Novocure, the Swiss maker of a wearable electric field therapy to treat certain cancers, has named veteran insider Frank Leonard as its chief executive, effective immediately. Leonard, who has worked at Novocure for 15 years and most recently as president, takes over for Ashley Cordova, who has resigned from the company but will remain on the payroll through May 2026.
The FDA’s initial clearance for Medtronic’s Hugo includes procedures to remove the prostate, kidneys and bladder, which cover about 230,000 surgeries annually in the U.S. (Medtronic)
Hugo is heading to the U.S., with Medtronic finally securing a stateside clearance for its robotic surgery platform.
On 1 December, the fortunes of the UK pharma sector changed radically, with the UK Government becoming the first in the world to secure a 0% US import tariff on pharmaceuticals. However, while zero tariffs may give UK pharma companies an edge over neighbouring EU and Swiss companies, the accompanying terms of the deal may have even more far-reaching consequences for the UK economy.
